Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127571 | 0.86 | TRIM24 (0.39) | HCRTR1TRIM24TRIM33KMT2ACASP6 | |
| SCHEMBL27870877 | 0.81 | METAP1 (0.46) | HCRTR1CASP6RAB9AHCRTR2ERN1 | |
| SCHEMBL16278038 | 0.79 | ERN1 (0.38) | TRIM24TRIM33KMT2ARAB9AERN1 | |
| SCHEMBL2686250 | 0.79 | ALDH1A1 (0.42) | HCRTR1TRIM24TRIM33KMT2ARAB9A | |
| SCHEMBL3679520 | 0.76 | MEN1 (0.46) | TRIM24TRIM33KMT2AERN1 | |
| SCHEMBL14840571 | 0.75 | ERN1 (0.45) | CYP11B2ERN1 | |
| SCHEMBL27918769 | 0.75 | KMO (0.44) | KMT2ACASP6RAB9AGRM5 | |
| SCHEMBL2687022 | 0.75 | KMT2A (0.50) | TRIM24TRIM33KMT2ARAB9AGRM5 | |
| SCHEMBL29912141 | 0.75 | KMT2A (0.50) | TRIM24TRIM33KMT2ARAB9AGRM5 | |
| SCHEMBL24014343 | 0.75 | F2RL1 (0.46) | KMT2ACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669052-B | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-110669052-A | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10131653-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155333-A1 | Heterocyclic Compound | HCRTR1, HCRTR2, OXTR | HCRTR1 1/4885TRIM24 4180/4885TRIM33 4763/4885 |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | HCRTR1 15/4885TRIM24 2412/4885TRIM33 3860/4885 |
| US-10131653-B2 | Heterocyclic compound | HCRTR1, HCRTR2, OXTR | HCRTR1 1/4885TRIM24 4180/4885TRIM33 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.